Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy
NCT ID: NCT02282449
Last Updated: 2016-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
209 participants
INTERVENTIONAL
2013-09-30
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Ensuring that these patients have safe and reliable access to the veins for chemotherapy is challenging, and sometimes a medical device is required to administer the chemotherapy into the veins.
A totally implanted venous access device, or port, is implanted under the skin of the arm and is attached to a small plastic catheter that enters into the veins. This device can be punctured with a needle when needed for treatment or testing.
Some types of these vein ports can rapidly inject fluids (power injection), and can be used for follow-up imaging studies, such as computed tomography, that are required to follow cancer treatment effectiveness. There are no publications of randomized patients discussing the impact of power injection upon TIVAD complications and device longevity for arm implantation. The investigators propose to compare the effectiveness of power injectable against non-power injectable ports to determine if they have different clinical performance and complications. Our results will impact the care provided to cancer patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The null hypothesis envisions both devices performing similarly in regards to chemotherapy and complications. However, the power injectable population will experience the high flow, large volume injections, may experience complications of injection extravasation and port damage due to the more vigorous injection parameters.
Trial Objectives:
1. To prospectively assess the functionality and complications of a power injectable vs. a non-power injectable TIVAD in a cohort of breast cancer patients requiring intravenous chemotherapy. The TIVAD will be randomly assigned to each patient.
2. Assess quality of life for subjects who have the two different TIVADs.
3. Facilitate device selection for future cancer patients requiring chemotherapy.
We will perform a randomized, prospective clinical trial of patients with cancer to compare a non-power injectable port, Cook Vital Mini Port (Cook Canada, Mississauga, ON), with a power injectable port, the AngioDynamics Smart Port CT Mini (AngioDynamics Inc., Manchester, GA, USA).
Adverse events, such as arm swelling, skin rash, and incision dehiscence, etc., will be tracked via an online reporting system, a patient registry, and by follow-up strategies related to imaging and clinical assessments at regular time intervals.
Patient Follow-up:
From the Insertion date, a 7 day post insertion telephone interview will be performed. Subsequently the following will be obtained at 3 months and 12 months post port insertion.
Clinical examination Venous Doppler US (arm/neck) Chest and arm X-ray QLQC30 questionnaire QLAVD-PA questionnaire Adverse Event Record
Details of Follow-up:
Clinical Examination:
Visual inspection of the arm, port implantation site, neck, and anterior chest.
1. Distended arm, neck or chest veins - Y/N - details
2. Swollen or edematous arm, neck, chest - Y/N - details
3. Skin rash - Y/N - details
4. Signs of arm infection - redness, swelling, purulent discharge - Y/N - details
5. Abnormal incision site of port insertion - Y/N - details
Venous Doppler Ultrasound (arm/neck):
Ultrasound will assess for vein thrombosis or narrowing.
Chest and arm x-rays:
Standard x-rays to include the arm from at least the elbow to axilla, full chest x-ray.
QLCC30 and QLAVD-PA:
Quality of Life surveys.
Adverse Events:
7 days, 3 months, 12 months, up to 24 months if possible - The patient will be contacted by telephone to determine if they have experienced any adverse events.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Power Injectable Port
The subjects randomized to this group will receive the newer, power injectable port.
Power Injectable Port (AngioDynamics Smart Port CT Mini)
The subjects will all receive power injectable port.
Non-Power Injectable Port
The subjects randomized to this group will receive the older, non-power injectable port.
Non-Power Injectable Port (Cook Vital Mini Port)
The subjects will all receive non-power injectable port.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Power Injectable Port (AngioDynamics Smart Port CT Mini)
The subjects will all receive power injectable port.
Non-Power Injectable Port (Cook Vital Mini Port)
The subjects will all receive non-power injectable port.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Those with uncorrectable blood clotting disorder;
* Pregnant women, as they will not be candidates for chemotherapy;
* Any person with an active infection or immunocompromised state;
* Those on oral or intravenous antibiotics on the day of TIVAD implantation.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Saskatchewan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brent Burbridge
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brent E Burbridge, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Medical Imaging, 103 Hospital Drive, Royal University Hospital, Saskatoon, SK, Canada S7N 0W8
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Imaging, Royal University Hospital, 103 Hospital Drive
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goossens GA, Stas M, Jerome M, Moons P. Systematic review: malfunction of totally implantable venous access devices in cancer patients. Support Care Cancer. 2011 Jul;19(7):883-98. doi: 10.1007/s00520-011-1171-3. Epub 2011 May 10.
Marcy PY, Chamorey E, Amoretti N, Benezery K, Bensadoun RJ, Bozec A, Poissonnet G, Dassonville O, Rame M, Italiano A, Peyrade F, Brenac F, Gallard JC. A comparison between distal and proximal port device insertion in head and neck cancer. Eur J Surg Oncol. 2008 Nov;34(11):1262-9. doi: 10.1016/j.ejso.2007.09.011. Epub 2007 Nov 5.
Goltz JP, Machann W, Noack C, Hahn D, Kickuth R. Feasibility of power contrast injections and bolus triggering during CT scans in oncologic patients with totally implantable venous access ports of the forearm. Acta Radiol. 2011 Feb 1;52(1):41-7. doi: 10.1258/ar.2010.100238.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-42
Identifier Type: -
Identifier Source: org_study_id